Literature DB >> 15703191

Myotonic dystrophy associated expanded CUG repeat muscleblind positive ribonuclear foci are not toxic to Drosophila.

Jonathan M Houseley1, Zongsheng Wang, Graham J R Brock, Judith Soloway, Ruben Artero, Manuel Perez-Alonso, Kevin M C O'Dell, Darren G Monckton.   

Abstract

Myotonic dystrophy type 1 is an autosomal dominant disorder associated with the expansion of a CTG repeat in the 3' untranslated region (UTR) of the DMPK gene. Recent data suggest that pathogenesis is predominantly mediated by a gain of function of the mutant transcript. In patients, these expanded CUG repeat-containing transcripts are sequestered into ribonuclear foci that also contain the muscleblind-like proteins. To provide further insights into muscleblind function and the pathogenesis of myotonic dystrophy, we generated Drosophila incorporating CTG repeats in the 3'-UTR of a reporter gene. As in patients, expanded CUG repeats form discrete ribonuclear foci in Drosophila muscle cells that co-localize with muscleblind. Unexpectedly, however, foci are not observed in all cell types and muscleblind is neither necessary nor sufficient for their formation. The foci are dynamic transient structures with short half-lifes that do not co-localize with the proteasome, suggesting they are unlikely to contain mis-folded proteins. However, they do co-localize with non-A, the human orthologs of which are implicated in both RNA splicing and attachment of dsRNA to the nuclear matrix. Muscleblind is also revealed as having a previously unrecognized role in stabilizing CUG transcripts. Most interestingly, Drosophila expressing (CUG)162 repeats has no detectable pathological phenotype suggesting that in contrast to expanded polyglutamine-containing proteins, neither the expanded CUG repeat RNA nor the ribonuclear foci are directly toxic.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703191     DOI: 10.1093/hmg/ddi080

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  39 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  Mechanisms of RNA-mediated disease.

Authors:  Jason R O'Rourke; Maurice S Swanson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

3.  Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.

Authors:  Mani S Mahadevan; Ramesh S Yadava; Qing Yu; Sadguna Balijepalli; Carla D Frenzel-McCardell; T David Bourne; Lawrence H Phillips
Journal:  Nat Genet       Date:  2006-07-30       Impact factor: 38.330

Review 4.  Break-induced replication links microsatellite expansion to complex genome rearrangements.

Authors:  Michael Leffak
Journal:  Bioessays       Date:  2017-06-16       Impact factor: 4.345

5.  Dystrophia myotonia: why focus on foci?

Authors:  R P Junghans
Journal:  Eur J Hum Genet       Date:  2009-01-28       Impact factor: 4.246

Review 6.  Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy.

Authors:  N Muge Kuyumcu-Martinez; Thomas A Cooper
Journal:  Prog Mol Subcell Biol       Date:  2006

7.  Distinct roles for Toll and autophagy pathways in double-stranded RNA toxicity in a Drosophila model of expanded repeat neurodegenerative diseases.

Authors:  Saumya E Samaraweera; Louise V O'Keefe; Gareth R Price; Deon J Venter; Robert I Richards
Journal:  Hum Mol Genet       Date:  2013-03-21       Impact factor: 6.150

8.  Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

Authors:  Benedikt Schoser; Lubov Timchenko
Journal:  Curr Genomics       Date:  2010-04       Impact factor: 2.236

9.  Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica Protein Kinase Gene.

Authors:  Beatriz Llamusí; Ruben Artero
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

10.  RNA gain-of-function in spinocerebellar ataxia type 8.

Authors:  Randy S Daughters; Daniel L Tuttle; Wangcai Gao; Yoshio Ikeda; Melinda L Moseley; Timothy J Ebner; Maurice S Swanson; Laura P W Ranum
Journal:  PLoS Genet       Date:  2009-08-14       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.